Back to mobile site

RBC Capital on Bristol-Myers Squibb Co. (BMY): 'Strong Execution Expected But May be Overshadowed by Key Binary Catalyst'

October 19, 2026 9:28 AM EDT Send to a Friend
RBC Capital analyst Trung Huynh reiterated a Sector Perform rating and $64.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login